fbpx

OPSENS RECEIVES dPR CLEARANCE FROM FDA

Opsens Receives dPR Clearance from the FDA Product approval will bolster U.S. commercial efforts Quebec City, Quebec, December 19, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) […]

Read More…

VISIT OPSENS AT SCAI FALL FELLOWS 2019

Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at the SCAI Fall Fellows 2019 Annual Meeting by attending Opsens’ complimentary educational symposium. The OptoWire features a large nitinol core with excellent torque response and […]

Read More…

OPSENS ANNOUNCES ENTRY INTO STRUCTURAL HEART MARKET

OPSENS ANNOUNCES ENTRY INTO STRUCTURAL HEART MARKET Expands core technology into fastest growing segment of cardiology devices Quebec City, Quebec, November 5, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces today it is expanding its medical device […]

Read More…

Visit Opsens at TCT 2019

Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at TCT 2019 (Transcatheter Cardiovascular Therapeutics 2019) by attending Opsens’ complimentary lunch  and educational symposium. Register Now! The OptoWire features a large nitinol core with excellent […]

Read More…

Visit Opsens at CVI 2019

Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at CVI 2019 (Cardiovascular Innovations 2019) by attending Opsens’ complimentary lunch  and educational symposium. Register Now! The OptoWire features a large nitinol core with excellent […]

Read More…

This website uses cookies to ensure you get the best experience on our website.